Therapeutic Use:

Indications for JENTADUETO XR:

Adjunct to diet and exercise in type 2 diabetes when treatment with both linagliptin and metformin is appropriate.

Limitations Of use:

Not for treatment of type 1 diabetes or diabetic ketoacidosis. Not studied in patients with history of pancreatitis.

Adult:

Individualize. Swallow whole. Take once daily with a meal. Currently not treated with metformin: initially 5mg/1000mg once daily. Already treated with metformin: start with 5mg linagliptin and current metformin dose once daily. Already treated with linagliptin and metformin or Jentadueto: switch to XR tabs containing 5mg linagliptin and current metformin dose once daily. Max 5mg/2000mg daily. Renal impairment (eGFR 30–45mL/min/1.73m2): not recommended. If eGFR <45mL/min/1.73m2, assess risk/benefit; discontinue if eGFR <30mL/min/1.73m2.